Targeted Degradation of EGFR and PKC Isoforms: Emerging Bifunctional and Peptidic Modalities in Oncology and Immune Regulation

Recent innovations in targeted protein degradation (TPD) extend beyond small-molecule PROTACs to encompass engineered peptides and recyclable ligand systems. Two complementary strategiesEGFR-directed peptide complexes and PKC-targeting bifunctional degradershighlight a mechanistic expansion of TPD into kinase-driven pathologies, offering new avenues for addressing cancer resistance, immune dysregulation, and receptor signaling with enhanced precision and modularity.